on behalf the ATHENA national HIV observational cohort Background: To describe the use of nonantiretroviral comedication and combination antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus (HCV) and to predict the potential for drug-drug interactions (DDIs) with direct-acting antivirals (DAAs) against HCV.
INTRODUCTION
Because of shared routes of transmission and overlapping at-risk populations, patients with HIV are commonly coinfected with hepatitis C virus (HCV). It is estimated that, worldwide, 2.3 million people live with an HIV/HCV coinfection. 1 In the Netherlands, 12% of the HIV-infected patients tested were positive for HCV antibody or HCV RNA. Most of these patients are men who have sex with men (46%) or current or former drug users (31%). 2 Both HIV [combination antiretroviral therapy (cART)] and HCV [direct-acting antivirals (DAAs)] treatments can be victims (substrates) and/or perpetrators (cause) of drug-drug interactions (DDIs). 3 For example, nevirapine is a strong inducer of cytochrome P450 (CYP) 3A4, and therefore interacts with velpatasvir (CYP3A4 substrate). 4 On the other hand, the combination of ombitasvir, paritaprevir/ritonavir +/2 dasabuvir (PrO+/2D), strongly inhibits CYP3A4, causing increased levels of rilpivirine (CYP3A4 substrate). 5 These examples demonstrate that DDIs could be a potential problem in HIV/HCV-coinfected patients. So far, this has been studied mainly focusing on cART/DAA interactions. [6] [7] [8] [9] However, treatment of coinfected patients is complicated in the aging HIV population, because these patients often have somatic or psychiatric comorbidities for which comedication is prescribed. Thus, besides cART, management of DDIs in HIV/HCV-coinfected patients should also focus on interactions between DAAs and these comedications. Furthermore, earlier publications in general did not include evaluations of the most modern DAAs, such as velpatasvir and grazoprevir/elbasvir, which are now recommended first-line agents.
We aimed to identify the use of comedication and cART and predicted DDIs of these medications with all currently available DAAs in a Dutch nationwide HIV/HCVcoinfected cohort.
METHODS
This retrospective, cross-sectional study, used the ATHENA database managed by the HIV monitoring Foundation (http://www.hiv-monitoring.nl). This is a Dutch, nationwide registry in which all HIV-infected patients in care who did not opt out are registered. All patients with a known HIV/HCV coinfection on January 1, 2015, were included (HCV RNA positive). These patients were not treated with DAAs before, as these drugs became available in the Netherlands on January 1, 2015. The included patients represent the total population of patients who could potentially be treated with DAAs, and comedication and cART were thus not altered because of DDIs with DAAs. The reported comedication and cART was used to predict DDIs using the database of the University of Liverpool (http://hep-druginteractions.org; September 2016).
This analysis was done in 4 steps: (1) identification of comedication used in the cohort; (2) prediction of DDIs between comedication and DAAs; (3) identification of cART used in the cohort; and (4) prediction of DDIs between cART and DAAs.
Identification of Comedication
All nonantiretroviral comedication was extracted from the database, from which a list was compiled of all unique comedications.
Prediction of DDIs Between Comedication and DAAs
The extracted list of comedications was used for the prediction of DDIs. Each drug was cross-checked if DDIs exist with one of the DAA regimens. We included all DAA regimens recommended in Dutch guidelines in November 2016. 10 DDIs were categorized as: (1) no clinically relevant DDI expected; (2) possible DDI expected, ie, monitor the patient or alter drug dosage/timing; (3) contraindication, do not coadminister; or (4) no information available in the Liverpool database. Category 2 and 3 DDIs were defined as clinically relevant. We reported per DAA regimen the number of comedications with a potential DDI.
After determination of the DDIs between the unique comedications and DAA regimens, we assessed the number of patients, per genotype, at risk for a clinically relevant DDI. We counted the patients who had at least one predicted DDI with any of the DAA regimens. Dutch recommendations of November 2016 were used to determine which DAA regimen can be used per genotype. 10 Patients with an unknown HCV genotype were analyzed with pan-genotypic regimens: sofosbuvir+dacla-tasvir and sofosbuvir+velpatasvir. We reported per genotype, the frequency of patients at risk for a DDI.
In addition, patients with DDIs were counted for those (1) with or without cirrhosis and those (2) ,60 or $60 years. Cirrhosis (METAVIR F3/F4) was defined using a pathology or Fibroscan report (stiffness .9.5 kPa).
Identification of cART
Antiretroviral drugs registered in the database were extracted and a list of antiretroviral drugs per patient was compiled.
Prediction of DDIs Between cART and DAAs
The compiled list of antiretroviral drugs was used for the prediction of DDIs. To simplify the analysis, only patients with a double-nucleoside reverse transcriptase inhibitors (NRTI) backbone and 1 additional drug were included. These additional drugs can be a (boosted) protease inhibitor (PI), (boosted) integrase inhibitor (INSTI), or a nonnucleoside reverse transcriptase inhibitor (NNRTI). These additional drugs usually cause DDIs and were therefore used in this analysis. Patients with other regimens were excluded. Per genotype and DAA regimen, the number of patients at risk for a DDI was reported.
Finally, patients using tenofovir disoproxil fumarate (TDF) and boosted PIs were identified. This combination interacts with ledipasvir and velpatasvir, causing possible renal toxicity. It is therefore recommended to discontinue TDF or the boosted PI before ledipasvir and velpatasvir therapy (category 2). Analyses were performed using IBM SPSS Statistics 20.
RESULTS
The ATHENA database contained data on 777 HIV/HCVcoinfected patients known to be in care on January 1, 2015. The majority of these patients were men (666; 86%). Median (range) age was 49.3 (23-80) years; 689 patients were aged ,60 years and 88 were $60 years. A METAVIR score of F0/F1/F2 was reported for 438 (56%) patients and F3/F4 for 181 (23%) patients (158 unknown). Genotypes 1 and 4 were most prevalent, in 495 (64%) and 139 (18%) patients, respectively (Supplemental Digital Content Table 1 , http://links.lww.com/QAI/B59).
Identification of Comedication
An overview of comedication use is presented in Figure 1 , showing that 488 patients used 156 unique nonantiretroviral comedications. Medication use varied from 1 to 14 prescriptions per patient (excluding cART); in total, 1245 prescriptions were reported. Most frequently used medications were drugs for opioid dependence (138; 11%), proton pump inhibitors (110; 9%), calcium supplements (77; 6%), selective serotonin reuptake inhibitors (56; 4%), platelet aggregation inhibitors (53; 4%), vitamin D (46; 4%), and statins (45; 4%). In Supplemental Digital Content Table 2 , http://links.lww.com/QAI/B59, these drug classes are broken down to the drugs that were prescribed to at least 10 patients (single molecules).
Prediction of DDIs Between Comedications and DAAs
Grazoprevir/elbasvir and sofosbuvir/velpatasvir had the lowest number of predicted DDIs with the 156 comedications. PrO6D and sofosbuvir/simeprevir account for the highest number of predicted category 2 and 3 interactions with the used comedication. Overall, the number of truly contraindicated drugs is low, with a maximum of 10 drugs for PrO6D. We were not able to predict potential DDIs of 23 drugs (category 4), as these drugs were unavailable in the Liverpool database (Fig. 1) .
Converting the number of drugs (156) to the number of patients with a category 2 or 3 DDI with any of the DAAs, we found that 299 patients were at risk. This concerns 205 (41%) genotype 1, 34 (36%) genotype 2/3, 54 (39%) genotype 4, and 6 (12%) patients with an unknown genotype. Furthermore, 269 (40%) patients aged ,60 years and 55 (77%) patients aged $60 years were at risk for a category 2 or 3 DDI with any of the DAA regimens. Similarly, 147 (34%) and 100 (55%) patients without and with cirrhosis, respectively, were at risk for a DDI.
Identification of cART
A total of 762 (98%) patients were treated with cART. The NRTI backbone containing TDF+emtricitabine was used by 536 (70%) of patients, and 103 (14%) patients used abacavir+lamivudine. Most patients used 1 additional (eg, PI, INSTI, NNRTI) antiretroviral drug (670; 88%) and 40 (5%) patients used more than 1 additional antiretroviral. Most frequently used additional drugs were NNRTIs (307; 46%), followed by the boosted PIs (247; 37%), and INSTIs (116; 17%). It should be noted that on the date of evaluation, January 1, 2015, dolutegravir had been available only for 2 months.
Prediction of DDIs Between cART and DAAs
Per genotype, the predicted DDIs per patient are shown in Figure 2 (n = 669). None of the patients with genotypes 1 and 4 would have to change their cART when treated with sofosbuvir/daclatasvir. However, the dosage of daclatasvir should be altered depending on some specific cART regimens. Ledipasvir and velpatasvir in combination with sofosbuvir can be safely used with all third additional drugs. However, 199 (31%) patients with genotype 1 or 4 used TDF with boosted PIs, which makes it necessary to switch either TDF or the PI. Comparably, in combination with velpatasvir, patients infected with all genotypes using TDF with a boosted PI (n = 231; 29%) are recommended to switch either TDF or the PI.
Grazoprevir/elbasvir causes the most category 3 DDIs, necessitating a change in the DAA or cART regimen. Other regimens with category 3 interactions were sofosbuvir with velpatasvir/simeprevir and PrO6D. For patients with genotype 2/3 or an unknown genotype, it is shown that sofosbuvir/daclatasvir can be used without switching the cART.
DISCUSSION
This cohort represents all Dutch HIV/HCV-coinfected patients in care in the Netherlands who might be treated with the novel DAAs. Most commonly used comedications reflect the characteristics of the HIV/HCV patient population, such as the drugs used for opioid dependence. 2 Other drug classes in the top 5 are comparable to HCV monoinfected patients in FIGURE 2. The number of patients predicted to have a drug interaction between cART and the various combinations of DAAs shown per genotype. Only patients with one additional (third) drug are included in this analysis (n = 670). Genotype 6 is excluded from this analysis, as only one patient was listed with genotype 6 (n = 669). Category 2: 30 mg: reduce the daclatasvir dose to 30 mg. Category 2: 90 mg: increase the daclatasvir dose to 90 mg. PrOD, ombitasvir, paritaprevir, ritonavir with dasabuvir; PrO, ombitasvir, paritaprevir, ritonavir; SOF + SIM, sofosbuvir and simeprevir; SOF + LED, sofosbuvir and ledipasvir; SOF + DAC, sofosbuvir and daclatasvir; SOF + VEL, sofosbuvir and velpatasvir; GRV + EBV, grazoprevir and elbasvir.
the Netherlands 11 and represent the aging HIV population with an increasing number of comorbidities. This is supported by our subgroup analysis in which patients aged $60 years had a higher risk of DDIs than patients aged ,60 years. Similarly, patients with cirrhosis had a higher predicted risk of DDIs than did patients without cirrhosis. This is comparable to the findings in HCV monoinfected patients. 12 PrO6D and sofosbuvir/simeprevir have the highest number of predicted DDIs with nonantiretroviral comedication, which is in line with previous studies. 6, 8, 9 Both combinations contain inhibitors of CYP3A4 (ie, ritonavir, simeprevir), which is the main drug-metabolizing enzyme. 5, 13 However, it should be mentioned that, in daily practice, these regimens are infrequently used because of side effects such as those related to DDIs and PIs.
Grazoprevir/elbasvir had the lowest number of DDIs with comedication because they have minimal influence on drug-enzymes and transporters. 14 One should notice that grazoprevir is a mild inhibitor of CYP3A4. Therefore, we recommend being careful with CYP3A4 substrates with a narrow therapeutic range. However, it remains unclear whether these DDIs are clinically relevant.
Sofosbuvir/daclatasvir can be easily combined with cART because of the possibility of a dose adaptation and no contraindicated cART regimens. Although ledipasvir has only category 2 DDIs, it is less favorable because it is not recommended with the combination of a boosted PI and TDF, an issue that would require a switch in cART in 31% of patients. This interaction, as well as the interaction with velpatasvir (29%), can also be avoided when switching from TDF to tenofovir alafenamide. Plasma concentrations of tenofovir alafenamide are not affected by ledipasvir. 15 In most countries, the separate agents, daclatasvir and sofosbuvir are in general a more expensive DAA regimen compared with the fixed-dose combinations with velpatasvir and ledipasvir and therefore prescribed in a lesser extent. In the Netherlands, the prices of DAAs are unknown and therefore not a criterion for selecting a DAA regimen. 10 It is striking that grazoprevir/elbasvir has the lowest number of interactions with nonantiretroviral comedication, but this combination has the highest number of DDIs with cART. Grazoprevir/elbasvir (and simeprevir) is contraindicated with all boosted PIs, NNRTIs (except rilpivirine), and elvitegravir/cobicistat; this makes it an unfavorable combination in this coinfected population because almost all patients would need to alter their cART regimen, if they are not already on raltegravir or dolutegravir. NNRTIs and PIs are most frequently used in our cohort, but with the introduction of dolutegravir, the use of NNRTIs and PIs decreased. 2 A limitation of the analysis is that patients with the most complicated cART regimens (eg, .1 additional drug, no NNRTI backbone) were excluded from the analysis presented in Figure 2 . These patients are probably the most-difficult-totreat HIV patients, because they have deviating cART regimens, and therefore, switching cART is probably not an option in these cases (eg, resistance, toxicity). For these patients, the treatment strategy is to use a DAA regimen with a least number of (possible) drug interactions.
Finally, we must comment that the majority of the DDIs, which are discussed in this article, are studied only in healthy volunteers and not in HIV/HCV-coinfected patients. These drug interaction studies in healthy volunteers give a good indication of the direction of the DDI; however, as healthy volunteers substantially differ from HIV/HCV-coinfected patients, the magnitude of the DDIs could differ because, for example, the exposure to DAAs and antiretroviral drugs is probably different in healthy volunteers and HIV/HCV patients. 16 Concluding, this study showed that comedication use in the aging HIV/HCV population is frequent and diverse and that there is a high potential of DDIs between DAAs plus comedication/cART. Combining the results from our analysis, from the perspective of potential DDIs with comedication and/or cART, the most favorable regimen seems to be sofosbuvir/daclatasvir.
ETHICS STATEMENT
At initiation, the ATHENA observational cohort was approved by the institutional review board of all participating centers. It has subsequently become an integral part of HIV care and includes pseudonymized data and stored plasma samples from HIV-infected patients living in the Netherlands and receiving care in one of the designated HIV treatment centers. Patients can opt out after being informed by their treating physician of the purpose of collection of data and samples. Data from patients who opt out are not included in the ATHENA database. Pseudonymized data may be used for scientific purposes without further review. Patients are informed that in case of future requests for use of stored plasma samples for scientific research, they will be asked for prior consent by their treating HIV physician. Data are pseudonymized before being provided to investigators. For the purpose of our analysis, only existing data have been used, and therefore no additional review or consent has been necessary.
